rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Preoperative GLP-1 Drugs May Help But Not Hinder Bariatric Surgery Outcomes in Diabetic Patients

RPEP-153642026Jain, Varun; McMullen, Colleen A; Kimbrough, Joy I; Rockich, Anna K; Davenport, Daniel L; Hawk, Gregory S; Nikolajczyk, Barbara S; Kern, Philip A; Fisher, Simon J; Steiner, Joshua P; Inabnet, William B; Starr, Marlene E
evidence
The takeaway

Preoperative GLP-1/GIP therapy in bariatric surgery candidates with T2D appears safe and may facilitate surgical preparation, with evidence against concerns about compromised postoperative weight loss.

Complementary, not competing

Preoperative GLP-1 drugs do not compromise bariatric surgery outcomes and may actually help prepare patients metabolically

What the researchers found

Preoperative GLP-1/GIP therapy: does not compromise post-bariatric weight loss; may optimize preoperative metabolic status; perioperative management guidelines needed; T2D patient focus.

Why it matters

With millions on GLP-1 drugs needing bariatric surgery, clear guidance on perioperative management is urgently needed.

How the study worked

Review of evidence on preoperative GLP-1/GIP therapy effects on bariatric surgery outcomes in T2D patients.

What this study cannot tell us

Review. Most data retrospective. Optimal perioperative GLP-1 management protocols not standardized.

How to read the evidence

Review of mostly retrospective evidence. Reassuring but guidelines needed.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs and bariatric surgery are complementary, not competing — preoperative GLP-1 use may actually enhance surgical outcomes.

Questions still open

  • Should GLP-1 drugs be continued through the perioperative period?
  • Would preoperative GLP-1 optimization improve surgical outcomes?
  • Could GLP-1 drugs be restarted post-surgery to prevent weight regain?

Common questions

Should I stop GLP-1 drugs before bariatric surgery?
Evidence suggests preoperative GLP-1 use does not compromise surgical weight loss outcomes. The main concern is aspiration risk during anesthesia, which is managed separately.
Do GLP-1 drugs help prepare for surgery?
Yes — by improving blood sugar, reducing weight, and optimizing metabolic status before surgery. This may improve surgical candidacy and reduce perioperative complications.

Read the original research

Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.

The Journal of surgical research, 319, 58-65

View on PubMed ↗Publisher’s paper ↗

Citation

Jain, Varun; McMullen, Colleen A; Kimbrough, Joy I; Rockich, Anna K; Davenport, Daniel L; Hawk, Gregory S; Nikolajczyk, Barbara S; Kern, Philip A; Fisher, Simon J; Steiner, Joshua P; Inabnet, William B; Starr, Marlene E. (2026). Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.. The Journal of surgical research, 319, 58-65. https://doi.org/10.1016/j.jss.2026.01.004